How should I evaluate the cause of lung fibrosis seen on high-resolution computed tomography (HRCT) involving the right upper lobe, posterior portion of the right lung, and the upper portion of the left lower lobe?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Evaluation of Lung Fibrosis on HRCT: Right Upper Lobe, Posterior Right Lung, and Upper Left Lower Lobe

The evaluation must begin with a systematic multidisciplinary approach integrating clinical assessment, detailed exposure history, pulmonary function tests, and consideration of surgical lung biopsy or transbronchial cryobiopsy when HRCT patterns are not definitive for usual interstitial pneumonia (UIP). 1

Initial Clinical Assessment

Critical History Elements to Obtain

Exposure Assessment - This is paramount given your HRCT distribution pattern:

  • Environmental antigens: Bird exposure, mold, hot tubs, humidifiers, feather bedding 2, 3
  • Occupational exposures: Organic dusts, chemicals, mineral particles (silica, asbestos) 1
  • Medication history: Drug-induced ILD must be excluded 1
  • Smoking history: Current/former smoking status and pack-years 4, 5

Connective Tissue Disease Screening - Essential to exclude CTD-ILD:

  • Systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, mixed connective tissue disease, inflammatory myopathies, systemic lupus erythematosus 1, 6
  • Look for: Raynaud's phenomenon, arthralgias, dry eyes/mouth, skin changes, muscle weakness
  • Obtain autoimmune serology panel 6

Physical Examination Findings:

  • Bibasilar inspiratory "velcro" crackles (suggests fibrosis) 1, 6
  • Digital clubbing (present in <50% of IPF cases) 1
  • Signs of connective tissue disease 6

HRCT Pattern Analysis

Your specific distribution (R upper lobe, posterior R lung, upper L lower lobe) is atypical for IPF, which characteristically shows subpleural, basal predominance 1, 4. This distribution raises several diagnostic considerations:

Key HRCT Features to Document:

Fibrotic patterns to identify:

  • Honeycombing: Clustered cystic airspaces with thick walls, subpleural location 1
  • Traction bronchiectasis/bronchiolectasis: Indicates established fibrosis 1, 3
  • Reticulation: Irregular linear opacities 1

Features suggesting alternative diagnoses:

  • Centrilobular nodules: Strongly suggests hypersensitivity pneumonitis over IPF 3, 1, 7
  • Mosaic attenuation: Suggests small airways disease, common in HP 3, 1
  • Ground-glass opacity:
    • If extensive (>30% of lung), consider DIP, HP, or organizing pneumonia rather than IPF 8, 1
    • If with traction bronchiectasis, suggests fibrotic process 2, 3
  • Upper/mid-lung predominance: Atypical for IPF; consider HP, sarcoidosis, silicosis 8, 3

Diagnostic Algorithm Based on HRCT Pattern

If HRCT Shows Definite UIP Pattern:

  • Subpleural, basal honeycombing with reticulation and traction bronchiectasis
  • No other features suggesting alternative diagnosis
  • Diagnosis of IPF can be made without biopsy IF other ILD causes excluded 1

If HRCT Shows Possible UIP or Indeterminate Pattern (Your Case):

Given your atypical distribution, this likely applies:

  1. Proceed to tissue diagnosis via:

    • Transbronchial lung cryobiopsy (TBLC): First-line if available at experienced center (>80% diagnostic yield) 5, 9
    • Surgical lung biopsy: If TBLC unavailable or contraindicated, after careful risk assessment 1
  2. Consider bronchoalveolar lavage (BAL):

    • Lymphocytosis ≥20% supports HP diagnosis 3
    • Increased neutrophils suggests UIP/IPF 4
    • Helps exclude infection, malignancy, eosinophilic pneumonia 6

Pulmonary Function Testing

Mandatory baseline tests 1:

  • Forced vital capacity (FVC) and total lung capacity: Restrictive pattern expected
  • DLCO: Early and sensitive marker of ILD; typically reduced
  • 6-minute walk test: Assess exercise capacity and oxygen desaturation
  • Resting arterial blood gas

Multidisciplinary Discussion

All cases require MDD involving 1, 4:

  • Pulmonologist experienced in ILD
  • Thoracic radiologist
  • Pathologist (if biopsy obtained)

Complex cases should be referred to expert ILD centers 1

Differential Diagnosis for Your Distribution Pattern

Given the upper lobe and posterior involvement, prioritize:

  1. Hypersensitivity pneumonitis (fibrotic):

    • Look for centrilobular nodules, mosaic attenuation, upper/mid-lung involvement 3, 7
    • BAL lymphocytosis supports diagnosis 3
    • May have UIP-like pattern but with distinguishing features 7
  2. Connective tissue disease-ILD:

    • Particularly systemic sclerosis (NSIP pattern common), rheumatoid arthritis (UIP pattern common) 6, 8
    • Check autoimmune serologies 6
  3. Chronic silicosis or asbestosis:

    • Upper lobe predominance in silicosis
    • Look for pleural plaques in asbestosis 8
  4. Sarcoidosis:

    • Upper/mid-lung predominance with nodules along bronchovascular bundles 8, 10
  5. Atypical IPF/UIP:

    • Less common but possible 10

Critical Pitfalls to Avoid

  • Do not diagnose IPF without excluding CTD and exposures - autoimmune serologies and detailed exposure history are mandatory 1
  • Do not rely on HRCT alone when pattern is atypical - your distribution warrants tissue diagnosis 1
  • Do not miss centrilobular nodules - these strongly favor HP over IPF 3, 7
  • Do not perform biopsy without risk assessment - age, comorbidities, and disease severity affect operative risk 1

References

Research

Diagnostic Approaches for Idiopathic Pulmonary Fibrosis.

Tuberculosis and respiratory diseases, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.